Zydus Lifesciences Limited Zydus Lifesciences Limited

Zydus Lifesciences Limited

ZYDUSLIFE

Classificação em ações #1758
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Preço da ação
$12.04
Valor de mercado
$12.01B
Variação (1 dia)
-2.15%
Variação (1 ano)
6.00%
País
IN
Negociar Zydus Lifesciences Limited (ZYDUSLIFE)

Categoria

Healthcare
Receita da Zydus Lifesciences Limited (ZYDUSLIFE)
Receita em Jun 2026 TTM: $3.16B
De acordo com os últimos relatórios financeiros da Zydus Lifesciences Limited, a receita atual da empresa (TTM) é $3.16B. Em 2025, a empresa obteve uma receita de $2.72B um aumento em relação a a receita do ano 2024, que foi de $2.34B. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Zydus Lifesciences Limited de 2004 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) $3.16B 16.11%
2025 $2.72B 15.92%
2024 $2.34B 11.77%
2023 $2.10B 5.37%
2022 $1.99B 1.17%
2021 $1.97B 4.00%
2020 $1.89B -0.21%
2019 $1.90B 3.69%
2018 $1.83B 26.46%
2017 $1.45B 1.62%
2016 $1.42B 2.63%
2015 $1.39B 15.37%
2014 $1.20B 3.47%
2013 $1.16B 15.71%
2012 $1.00B 0.20%
2011 $1.00B 22.04%
2010 $820.89M 45.59%
2009 $563.82M -0.43%
2008 $566.27M 37.48%
2007 $411.90M 26.93%
2006 $324.50M 14.00%
2005 $284.66M 3.30%
2004 $275.56M 0.00%
Receita de empresas similares ou concorrentes